vs

Side-by-side financial comparison of ESCALADE INC (ESCA) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

RIGEL PHARMACEUTICALS INC is the larger business by last-quarter revenue ($69.8M vs $62.6M, roughly 1.1× ESCALADE INC). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs 5.9%, a 378.1% gap on every dollar of revenue. On growth, RIGEL PHARMACEUTICALS INC posted the faster year-over-year revenue change (21.2% vs -2.2%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 4.5%).

Escalade Inc is a global sporting goods manufacturer and distributor that offers basketball systems, archery equipment, table tennis gear, game tables, and outdoor recreation accessories. It operates primarily across North America, Europe, and Asia Pacific, serving consumer retail, commercial fitness, and specialty sports segments.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

ESCA vs RIGL — Head-to-Head

Bigger by revenue
RIGL
RIGL
1.1× larger
RIGL
$69.8M
$62.6M
ESCA
Growing faster (revenue YoY)
RIGL
RIGL
+23.4% gap
RIGL
21.2%
-2.2%
ESCA
Higher net margin
RIGL
RIGL
378.1% more per $
RIGL
384.0%
5.9%
ESCA
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
4.5%
ESCA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESCA
ESCA
RIGL
RIGL
Revenue
$62.6M
$69.8M
Net Profit
$3.7M
$268.1M
Gross Margin
27.7%
91.5%
Operating Margin
8.2%
33.2%
Net Margin
5.9%
384.0%
Revenue YoY
-2.2%
21.2%
Net Profit YoY
37.1%
1769.2%
EPS (diluted)
$0.27
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESCA
ESCA
RIGL
RIGL
Q4 25
$62.6M
$69.8M
Q3 25
$67.8M
$69.5M
Q2 25
$54.3M
$101.7M
Q1 25
$55.5M
$53.3M
Q4 24
$63.9M
$57.6M
Q3 24
$67.7M
$55.3M
Q2 24
$62.5M
$36.8M
Q1 24
$57.3M
$29.5M
Net Profit
ESCA
ESCA
RIGL
RIGL
Q4 25
$3.7M
$268.1M
Q3 25
$5.6M
$27.9M
Q2 25
$1.8M
$59.6M
Q1 25
$2.6M
$11.4M
Q4 24
$2.7M
$14.3M
Q3 24
$5.7M
$12.4M
Q2 24
$2.8M
$-1.0M
Q1 24
$1.8M
$-8.2M
Gross Margin
ESCA
ESCA
RIGL
RIGL
Q4 25
27.7%
91.5%
Q3 25
28.1%
93.2%
Q2 25
24.7%
95.6%
Q1 25
26.7%
91.7%
Q4 24
24.9%
89.9%
Q3 24
24.8%
85.5%
Q2 24
24.2%
92.4%
Q1 24
25.0%
93.1%
Operating Margin
ESCA
ESCA
RIGL
RIGL
Q4 25
8.2%
33.2%
Q3 25
10.8%
40.9%
Q2 25
4.8%
60.1%
Q1 25
6.6%
23.9%
Q4 24
7.1%
28.9%
Q3 24
11.8%
25.4%
Q2 24
7.1%
1.2%
Q1 24
5.3%
-23.6%
Net Margin
ESCA
ESCA
RIGL
RIGL
Q4 25
5.9%
384.0%
Q3 25
8.2%
40.2%
Q2 25
3.4%
58.6%
Q1 25
4.7%
21.5%
Q4 24
4.2%
24.9%
Q3 24
8.4%
22.5%
Q2 24
4.5%
-2.8%
Q1 24
3.1%
-27.9%
EPS (diluted)
ESCA
ESCA
RIGL
RIGL
Q4 25
$0.27
$14.11
Q3 25
$0.40
$1.46
Q2 25
$0.13
$3.28
Q1 25
$0.19
$0.63
Q4 24
$0.20
$0.82
Q3 24
$0.40
$0.70
Q2 24
$0.20
$-0.06
Q1 24
$0.13
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESCA
ESCA
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$155.0M
Total DebtLower is stronger
$18.5M
$52.5M
Stockholders' EquityBook value
$173.2M
$391.5M
Total Assets
$222.1M
$513.6M
Debt / EquityLower = less leverage
0.11×
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESCA
ESCA
RIGL
RIGL
Q4 25
$155.0M
Q3 25
$137.1M
Q2 25
$108.4M
Q1 25
$77.1M
Q4 24
$77.3M
Q3 24
$61.1M
Q2 24
$49.1M
Q1 24
$49.5M
Total Debt
ESCA
ESCA
RIGL
RIGL
Q4 25
$18.5M
$52.5M
Q3 25
$60.0M
Q2 25
$60.0M
Q1 25
$60.0M
Q4 24
$25.6M
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Q1 24
$60.0M
Stockholders' Equity
ESCA
ESCA
RIGL
RIGL
Q4 25
$173.2M
$391.5M
Q3 25
$172.3M
$117.6M
Q2 25
$168.3M
$81.9M
Q1 25
$168.8M
$18.6M
Q4 24
$169.0M
$3.3M
Q3 24
$170.1M
$-14.6M
Q2 24
$166.0M
$-29.9M
Q1 24
$164.7M
$-31.7M
Total Assets
ESCA
ESCA
RIGL
RIGL
Q4 25
$222.1M
$513.6M
Q3 25
$232.5M
$242.5M
Q2 25
$218.3M
$206.7M
Q1 25
$222.1M
$176.0M
Q4 24
$226.3M
$164.0M
Q3 24
$244.9M
$139.4M
Q2 24
$243.1M
$128.4M
Q1 24
$256.3M
$126.5M
Debt / Equity
ESCA
ESCA
RIGL
RIGL
Q4 25
0.11×
0.13×
Q3 25
0.51×
Q2 25
0.73×
Q1 25
3.23×
Q4 24
0.15×
18.25×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESCA
ESCA
RIGL
RIGL
Operating Cash FlowLast quarter
$14.9M
$22.0M
Free Cash FlowOCF − Capex
$13.7M
FCF MarginFCF / Revenue
21.8%
Capex IntensityCapex / Revenue
2.0%
Cash ConversionOCF / Net Profit
4.02×
0.08×
TTM Free Cash FlowTrailing 4 quarters
$28.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESCA
ESCA
RIGL
RIGL
Q4 25
$14.9M
$22.0M
Q3 25
$-965.0K
$24.0M
Q2 25
$13.3M
$30.5M
Q1 25
$3.8M
$-893.0K
Q4 24
$12.3M
$14.5M
Q3 24
$10.5M
$21.7M
Q2 24
$13.3M
$302.0K
Q1 24
$7.0K
$-5.0M
Free Cash Flow
ESCA
ESCA
RIGL
RIGL
Q4 25
$13.7M
Q3 25
$-1.3M
Q2 25
$12.9M
Q1 25
$3.2M
Q4 24
$11.7M
Q3 24
$10.2M
Q2 24
$12.5M
Q1 24
$-350.0K
FCF Margin
ESCA
ESCA
RIGL
RIGL
Q4 25
21.8%
Q3 25
-1.9%
Q2 25
23.7%
Q1 25
5.9%
Q4 24
18.4%
Q3 24
15.0%
Q2 24
20.0%
Q1 24
-0.6%
Capex Intensity
ESCA
ESCA
RIGL
RIGL
Q4 25
2.0%
Q3 25
0.4%
Q2 25
0.8%
Q1 25
1.0%
Q4 24
0.9%
Q3 24
0.5%
Q2 24
1.3%
Q1 24
0.6%
Cash Conversion
ESCA
ESCA
RIGL
RIGL
Q4 25
4.02×
0.08×
Q3 25
-0.17×
0.86×
Q2 25
7.28×
0.51×
Q1 25
1.45×
-0.08×
Q4 24
4.55×
1.01×
Q3 24
1.85×
1.75×
Q2 24
4.67×
Q1 24
0.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons